Solutions for Cellular Senescence and Tumor Therapy
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides comprehensive solutions and services to study the relationship between human cellular senescence and tumorigenesis and development, and to provide tumor treatment strategies targeting senescent cells to help researchers successfully achieve their research goals.
Cellular senescence is a normal stress response of living organisms that suppresses tumorigenesis early in life; however, it is also a fundamental aging process that drives the onset of senescent phenotypes and age-related diseases late in life, which include numerous degenerative and proliferative disorders. Numerous studies have shown that SASP molecules expressed by senescent cells have a two-fold effect on the cell and the organism: on the one hand, it inhibits the development of tumor cells and removes abnormal and damaged cells from the body; on the other hand, it promotes tumor development under certain physiological conditions and makes tumor cells resistant to chemotherapeutic drugs. It has been confirmed that in the context of radiotherapy and chemotherapy, adjuvant therapy to eliminate senescent cells can enhance the killing ability of radiotherapy and chemotherapy on tumor cells. Therefore, the study of senescent cells may provide a new strategy for tumor prevention and treatment.
Cellular senescence has a "double-edged sword" effect in tumor progression. However, the specific biological mechanisms by which senescent cells affect the efficacy of tumor therapy through their autonomy and non-autonomy are not yet clear. Here, Alfa Oncology has established an innovative tumor microenvironment center technology platform and is developing several technologies designed to help global collaborators investigate tumor treatment strategies that target senescent cells. Understanding the relationship between human cellular senescence and tumorigenesis and progression provides guidance to improve tumor therapeutic efficacy and promotes research on the basic and clinical applications of cellular senescence in tumor therapy.
Key strategies and technologies
In the study of targeting senescent cells for tumor therapy, Alfa Oncology' main strategies include but are not limited to:
- Targeting senescence-specific pathways
- Directed elimination of senescent cells
- Immune-mediated interventions
- Blocking prosurvival pathways
- Senolytic combinations
- Induction of cellular senescence for antitumor therapy
- Oncogene-induced cellular senescence
- Chemotherapy/radiation-induced cellular senescence
- Cell cycle inhibition induced cellular senescence
- Telomerase inhibition induced cellular senescence
- Regulation of epigenome induced cellular senescence
- Targeting of tumor suppressor genes or oncogenes
The technologies involved in the services provided by Alfa Oncology for research targeting senescent cells include but are not limited to:
- Flow cytometry combined with histological or cytochemical methods
- Fluorescent sensors
- Positron emission tomography sensors
- Senescence detection in liquid biopsies
- Nanoparticle-based imaging for targeted delivery of contrast agents
Note: The key strategies and technologies we focus on are always up to date, please contact us by email for more up-to-date and relevant information.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.